FDAFDA · Food and drugs·Recall number D-0727-2026
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05
Published July 29, 2026 · Recall initiated: July 16, 2026
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of Particulate Matter: Hair was found in products
What to do
Voluntary: Firm initiated · Letter
Recall details
- Brand
- NAROPIN
- Manufacturer
- Fresenius Kabi USA, LLC
- Distributor
- Nationwide within in the USA
- UPC
- 0363323286033
- Lot
- Lot #: 6133436, Exp. Date 10/2028
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Sell products like this?
Recalert watches your whole catalog for recalls like this one, automatically.